Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML.
作者信息
Weisberg E, Deng X, Choi H G, Barrett R, Adamia S, Ray A, Moreno D, Kung A L, Gray N, Griffin J D
出版信息
Leukemia. 2010 Jul;24(7):1375-8. doi: 10.1038/leu.2010.107. Epub 2010 May 27.
Abstract
摘要
相似文献
1
Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML.
Leukemia. 2010 Jul;24(7):1375-8. doi: 10.1038/leu.2010.107. Epub 2010 May 27.
2
ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells.
Leukemia. 2010 Apr;24(4):869-72. doi: 10.1038/leu.2009.300. Epub 2010 Jan 28.
3
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Clin Cancer Res. 2006 Oct 1;12(19):5869-78. doi: 10.1158/1078-0432.CCR-06-0980.
4
HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance.
Leukemia. 2010 Oct;24(10):1807-9. doi: 10.1038/leu.2010.169. Epub 2010 Aug 12.
5
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
Blood. 2007 May 1;109(9):4006-15. doi: 10.1182/blood-2006-09-045039. Epub 2007 Jan 11.
6
INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
Blood. 2007 Jan 1;109(1):306-14. doi: 10.1182/blood-2006-03-013250. Epub 2006 Sep 5.
7
Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
Leuk Res. 2015 Jan;39(1):65-71. doi: 10.1016/j.leukres.2014.10.009. Epub 2014 Nov 11.
8
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
Blood. 2004 Oct 15;104(8):2532-9. doi: 10.1182/blood-2004-05-1851. Epub 2004 Jul 15.
9
Rapid recognition of drug-resistance/sensitivity in leukemic cells by Fourier transform infrared microspectroscopy and unsupervised hierarchical cluster analysis.
Analyst. 2013 Jul 21;138(14):3934-45. doi: 10.1039/c2an36393c.
10
Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Oncotarget. 2016 Apr 5;7(14):18204-18. doi: 10.18632/oncotarget.7569.
引用本文的文献
1
Current and future of targeted therapies against BCR::ABL kinases.
J Egypt Natl Canc Inst. 2025 Apr 7;37(1):12. doi: 10.1186/s43046-025-00263-5.
2
Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
Acta Pharmacol Sin. 2014 Mar;35(3):401-9. doi: 10.1038/aps.2013.180. Epub 2014 Feb 3.
3
Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.
PLoS One. 2012;7(8):e43437. doi: 10.1371/journal.pone.0043437. Epub 2012 Aug 16.
4
Pushing the limits of targeted therapy in chronic myeloid leukaemia.
Nat Rev Cancer. 2012 Jul 24;12(8):513-26. doi: 10.1038/nrc3317.
5
Targeting IAP proteins for therapeutic intervention in cancer.
Nat Rev Drug Discov. 2012 Feb 1;11(2):109-24. doi: 10.1038/nrd3627.
6
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.
Cancer Res. 2011 May 1;71(9):3189-95. doi: 10.1158/0008-5472.CAN-10-3224. Epub 2011 Apr 19.
7
Using NMR to study fast dynamics in proteins: methods and applications.
Curr Opin Pharmacol. 2010 Dec;10(6):723-30. doi: 10.1016/j.coph.2010.09.006. Epub 2010 Oct 8.
8
ABL tyrosine kinases: evolution of function, regulation, and specificity.
Sci Signal. 2010 Sep 14;3(139):re6. doi: 10.1126/scisignal.3139re6.
9
Real-time fluorescent resonance energy transfer analysis to monitor drug resistance in chronic myelogenous leukemia.
Mol Cancer Ther. 2010 Nov;9(11):3065-73. doi: 10.1158/1535-7163.MCT-10-0623. Epub 2010 Sep 3.
本文引用的文献
1
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.
Blood. 2010 May 27;115(21):4206-16. doi: 10.1182/blood-2009-11-251751. Epub 2010 Mar 18.
2
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.
Nature. 2010 Jan 28;463(7280):501-6. doi: 10.1038/nature08675. Epub 2010 Jan 13.
3
Crystal structure of the T315I mutant of AbI kinase.
Chem Biol Drug Des. 2007 Sep;70(3):171-81. doi: 10.1111/j.1747-0285.2007.00556.x.
4
Rational design of inhibitors that bind to inactive kinase conformations.
Nat Chem Biol. 2006 Jul;2(7):358-64. doi: 10.1038/nchembio799.
5
Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
Nat Chem Biol. 2006 Feb;2(2):95-102. doi: 10.1038/nchembio760. Epub 2006 Jan 15.
6
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
Cancer Cell. 2005 Feb;7(2):129-41. doi: 10.1016/j.ccr.2005.01.007.
7
Overriding imatinib resistance with a novel ABL kinase inhibitor.
Science. 2004 Jul 16;305(5682):399-401. doi: 10.1126/science.1099480.
8
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
Science. 2001 Aug 3;293(5531):876-80. doi: 10.1126/science.1062538. Epub 2001 Jun 21.
Zotero 插件